% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koeglsperger:284366,
      author       = {Koeglsperger, Thomas and Berberovic, Emir and Dresel,
                      Christian and Haferkamp, Sebastian and Kassubek, Jan and
                      Müller, Rahel and Oehlwein, Christian and Paus, Sebastian
                      and Urban, Peter Paul},
      title        = {{R}eal-world experience with continuous subcutaneous
                      foslevodopa/foscarbidopa infusion: insights and
                      recommendations.},
      journal      = {Journal of neural transmission},
      volume       = {133},
      number       = {2},
      issn         = {0375-9245},
      address      = {Wien [u.a.]},
      publisher    = {Springer},
      reportid     = {DZNE-2026-00134},
      pages        = {347 - 359},
      year         = {2026},
      abstract     = {Traditional advanced therapies in Parkinson's disease (PD)
                      with motor fluctuations and dyskinesias like continuous
                      apomorphine infusion (CSAI), levodopa-carbidopa intestinal
                      gel (LCIG), levodopa-carbidopa entacapone intestinal gel
                      (LECIG), or deep brain stimulation (DBS) have played a
                      central role in managing therapy-related complications.
                      Recently, continuous subcutaneous foslevodopa/foscarbidopa
                      infusion (CSFLI) has emerged as a novel therapeutic option.
                      This manuscript provides insights from one year of
                      real-world experience with CSFLI, addressing critical
                      questions that clinicians face when selecting the most
                      appropriate therapy for advanced PD. Our discussion centers
                      on key considerations for patient selection, exploring which
                      individuals may benefit more from CSFLI compared to other
                      device-aided therapies. We highlight CSFLI's advantages in
                      flexibility and ease of use but also consider limitations,
                      particularly its side effects, such as skin-related issues.
                      Recommendations are presented on how to prevent and manage
                      these adverse effects to maximize patient compliance and
                      therapeutic success. Additionally, the paper examines
                      strategies for optimizing concurrent oral medications when
                      combined with CSFLI, providing guidance on balancing pump
                      infusion with necessary adjunctive oral treatments.},
      subtyp        = {Review Article},
      keywords     = {Humans / Parkinson Disease: drug therapy / Antiparkinson
                      Agents: administration $\&$ dosage / Antiparkinson Agents:
                      adverse effects / Levodopa: administration $\&$ dosage /
                      Levodopa: adverse effects / Carbidopa: administration $\&$
                      dosage / Carbidopa: adverse effects / Drug Combinations /
                      Infusions, Subcutaneous / Advanced Treatment (Other) /
                      Foslevodopa/Foscarbidopa (Other) / Motor Fluctuations
                      (Other) / Parkinson’s disease (Other) / Antiparkinson
                      Agents (NLM Chemicals) / Levodopa (NLM Chemicals) /
                      Carbidopa (NLM Chemicals) / Drug Combinations (NLM
                      Chemicals) / carbidopa, levodopa drug combination (NLM
                      Chemicals)},
      cin          = {Clinical Research (Munich)},
      ddc          = {610},
      cid          = {I:(DE-2719)1111015},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40121314},
      doi          = {10.1007/s00702-025-02911-5},
      url          = {https://pub.dzne.de/record/284366},
}